Danielle C. Turner

Danielle C. Turner

Auto-generated profile, based on publicly available information

Danielle C. Turner

University of Cambridge, Department of Psychiatry, Box 189, Addenbrooke's Hospital, Cambridge, CB2 2QQ UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2004 in Neuropsychopharmacology
Verified
Journal Article
Closed access
DTDanielle C Turner
Danielle C Turner
LCLuke Clark
Luke Clark
EPEdith Pomarol-Clotet
Edith Pomarol-Clotet
PMPeter McKenna
Peter McKenna
TRTrevor W Robbins
Trevor W Robbins
BSBarbara J Sahakian
Barbara J Sahakian

27 August 2004 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
DTDanielle C. Turner
Danielle C. Turner
ABAndrew D. Blackwell
Andrew D. Blackwell
JDJonathan H. Dowson
Jonathan H. Dowson
AMAndrew McLean
Andrew McLean
BSBarbara J. Sahakian
Barbara J. Sahakian

1 April 2006 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
DTDanielle Turner
Danielle Turner
Modafinil (Provigil) is a novel wakefulness-promoting agent that has been shown to have greater efficacy than placebo in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. In particular, three large, drug-company sponsored trials of a film-coated formulation of modafinil (modafinil-ADHD; Sparlon) in children and adolescents with ADHD demonstrated consistent improvements in ADHD symptoms compared with placebo. Mean reductions in symptom ratings (measured using the ADHD-Rating Scale-IV school version questionnaire) ranged from 15.0 to 19.7 (7.3 to 10.1 for placebo). The most common adverse events were insomnia, headache and decreased appetite. Modafinil was generally well tolerated with most side effects considered mild to moderate in severity. Modafinil may have advantages over current therapies for ADHD in that it can be administered once daily and has fewer reinforcing properties than traditional stimulants. Modafinil could potentially be a valuable new treatment option for patients with ADHD. However, rigorous comparative studies with current first-line treatments for ADHD and longer-term independent studies are necessary before modafinil's role in the treatment of ADHD can be fully established.

13 January 2006 in Poiesis & Praxis
Verified
Journal Article
Closed access
PDF file
DTDanielle C. Turner
Danielle C. Turner
BSBarbara J. Sahakian
Barbara J. Sahakian

6 April 2006
Verified
Book Chapter
Closed access
DTDanielle C. Turner
Danielle C. Turner
BSBarbara J. Sahakian
Barbara J. Sahakian
Progress in Neurotherapeutics and Neuropsychopharmacology - April 2006